Novartis AG (TSX:NVS)
| Market Cap | 410.33B +14.6% |
| Revenue (ttm) | 81.44B +1.8% |
| Net Income | 14.24B -30.3% |
| EPS | 0.74 -28.3% |
| Shares Out | n/a |
| PE Ratio | 41.07 |
| Forward PE | 15.62 |
| Dividend | 0.87 (2.86%) |
| Ex-Dividend Date | Mar 11, 2026 |
| Volume | 105 |
| Open | 30.47 |
| Previous Close | 30.28 |
| Day's Range | 30.47 - 30.47 |
| 52-Week Range | 24.21 - 32.55 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 27, 2026 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia ... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial numbers in USD Financial StatementsNews
Novartis Reaffirms Sales Targets as Drug Trial Results and FDA Talks Loom
Novartis NYSE: NVS executives outlined a slate of upcoming drug-trial results and regulatory discussions across immunology, cardiovascular disease, oncology and neuroscience, while reiterating sales a...
Novartis Says AI Is Speeding Drug Discovery and Trials, but Clinical Payoff Remains Unproven
Novartis NYSE: NVS is applying artificial intelligence across drug research and clinical development, with executives reporting faster trial enrollment and drug candidate selection while cautioning th...
Novartis CEO Vas Narasimhan on Anthropic IPO: I'm incredibly proud, and it's a very exciting day
Vas Narasimhan, Novartis CEO and Anthropic Board of Directors member, joins 'Squawk on the Street' to discuss Anthropic's historic IPO, safety risks around new AI models, upside risk, and more.
Watch CNBC's full interview with Novartis CEO Vas Narasimhan
Vas Narasimhan, Novartis CEO and Anthropic Board of Directors member, joins 'Squawk on the Street' to discuss Anthropic's historic IPO, safety risks around new AI models, upside risk, and more.
Novartis CEO Vas Narasimhan on Anthropic IPO: I'm incredibly proud, and it's a very exciting day
Vas Narasimhan, Novartis CEO and Anthropic Board of Directors member, joins 'Squawk on the Street' to discuss Anthropic's historic IPO, safety risks around new AI models, upside risk, and more.
Novartis Targets 5% Annual Sales Growth Through 2031 Despite Patent Expirations
Novartis NYSE: NVS expects annual sales growth of 5% from 2026 through 2031 and average mid-single-digit growth into the mid-2030s, as the drugmaker looks to offset patent expirations with newer medic...
Novartis AG Projects +5% cc1 Sales CAGR Through 2031 and Upgrades Peak Sales Guidance for Key Brands
Novartis AG announced that it has rolled forward its mid-term guidance to 2026-2031, expecting net sales to grow at a +5% cc1 CAGR. The company also reported that its core operating income margin is o...
Novartis AG Transcript: Meet Novartis Management 2026 Part 3
AI is accelerating clinical and research workflows, including faster trial planning, shorter candidate timelines and three novel neurodegeneration targets advancing. Differentiation rests on organized historical data, scientific expertise and redesigned R&D processes.
Novartis AG Press release: FY 2026
Novartis AG issued a press release on November 19, 2026, disclosing material business information to investors.
Novartis AG Slides: FY 2026
Novartis AG has posted slides in relation to its FY 2026 quarterly earnings report, which was published on November 19, 2026.
Novartis trims medium-term growth target, shares fall
Swiss drugmaker Novartis is targeting annual sales growth of 5% through 2031, the lower end of its previous six-year guidance, as looming patent expiries and a series of late-stage trial setbacks incr...
Novartis projects +5% cc sales CAGR through 2031
Novartis (NVS) rolled forward its mid-term guidance to 2026-2031, with net sales expected to grow at a +5% cc CAGR, and core operating income margin on track to return to…
Novartis AG Transcript: Meet Novartis Management 2026 Part 2
Immunology updates highlighted ianalumab’s two-year Sjögren’s results and a multi-billion outlook, alongside Cosentyx’s $8B 2027 target. Leqvio outcomes, oncology franchises and neuroscience programs remain key catalysts, with pivotal data and regulatory discussions ahead.
Novartis AG Press release: FY 2026
Novartis AG issued a press release on November 19, 2026, disclosing material business information to investors.
Novartis AG Slides: FY 2026
Novartis AG has posted slides in relation to its FY 2026 quarterly earnings report, which was published on November 19, 2026.
Novartis bets on bigger blockbusters to power growth, forecasting 5% annual sales through 2031
Ahead of its Capital Markets Day on Thursday, Novartis upgraded its peak sales outlook for three of its blockbuster drugs to a combined $18 billion, up from a previous forecast of a combined $14 billi...
Novartis AG Transcript: Meet Novartis Management 2026 Part 1
Guidance calls for 5% sales growth through 2031, 40% core margin by 2029 and mid-single-digit average growth through 2035. A broad late-stage pipeline, improving R&D productivity and scaled AI underpin the outlook.
Novartis AG Press release: FY 2026
Novartis AG issued a press release on November 19, 2026, disclosing material business information to investors.
Novartis AG Slides: FY 2026
Novartis AG has posted slides in relation to its FY 2026 quarterly earnings report, which was published on November 19, 2026.
Novartis Projects 5% Annual Sales Growth In CC Through 2031, Sustained Growth Over Long Term
(RTTNews) - Swiss drug major Novartis AG (NVS, NOVN.SW) Thursday announced its mid-term guidance to 2026-2031, with net sales expected to grow 5 percent at constant currency CAGR. The firm added that ...
Novartis Sees Sales Growth Through 2031
The drugmaker expects annual sales growth of 5% from 2026 to 2031, from a previous forecast of 5% to 6% over the 2025-30 period.
Novartis targets 5% annual sales growth through 2031
Swiss drugmaker Novartis on Thursday outlined new mid-term sales targets that were at the lower end of the range it had given a year earlier, ahead of its annual investor event in London.
Novartis projects +5% cc¹ sales CAGR through 2031 and sustained mid-single-digit growth over the long term
Ad hoc announcement pursuant to Art. 53 LR Net sales expected to grow at a +5% cc¹ CAGR from 2026 to 2031; core operating income margin¹ on track to return to 40%+ by 2029 Peak sales guidance upgrad...
Novartis reports FDA approves Cosentyx for polymyalgia rheumatica
Novartis (NVS) announced that the U.S. Food and Drug Administration approved Cosentyx 150 mg for the treatment of adult patients with polymyalgia rheumatica who have had an inadequate response to…
Novartis' Cosentyx Wins FDA Approval As First Anti-IL-17 Biologic For Polymyalgia Rheumatica
(RTTNews) - On Tuesday, Novartis AG (NVS) said the U.S. FDA approved Cosentyx 150 mg for adults with polymyalgia rheumatica who have responded inadequately to corticosteroids or cannot tolerate steroi...